Research Papers:

Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells

Yaru Shi, Zhenlong Li, Ran Chen, Jiang Zhang, Xuefei Hu, Cong He, Qiong Su, Hongdou Ma, Hua Ren, Min Qian, Shufang Cuiand and Wenzheng Jiang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:75038-75049. https://doi.org/10.18632/oncotarget.20500

Metrics: PDF 1270 views  |   HTML 4620 views  |   ?  


Yaru Shi1,*, Zhenlong Li1,*, Ran Chen1, Jiang Zhang1, Xuefei Hu1, Cong He1, Qiong Su1, Hongdou Ma1, Hua Ren1, Min Qian1, Shufang Cui2 and Wenzheng Jiang1

1Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, China

2Laboratory Animal Center, Second Military Medical University, Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Wenzheng Jiang, email: [email protected]

Shufang Cui, email: [email protected]

Keywords: multiple sclerosis, EAE, H3R, immethridine, dendritic cell

Received: August 23, 2016    Accepted: July 29, 2017    Published: August 24, 2017


Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated demyelination and degeneration of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) is the preferential experimental rodent model for MS. Previous study demonstrated histamine H3 receptor (H3R) was an important factor in pathophysiology of EAE and immethridine was the most selective agonist of H3R. However, whether immethridine has therapeutic effect on EAE and its mechanism remained to be defined. Here we constructed EAE mouse model by immunization of MOG35-55 peptides with complete Freund’s adjuvant, immethridine was used to treat EAE and its therapeutic effect was evaluated. The results showed that the treatment of immethridine could alleviate EAE. The percentage of Th1 and Th17 in the spleen from the treated EAE mice decreased and the surface molecules such as CD40, CD86 or MHCII on dendritic cells (DCs) were also down-regulated. To understand the effect of immethridine on DCs, bone marrow-derived DCs were prepared and the immunological functions were analyzed. The data demonstrated that immethridine could change the expression profiles of cytokines in DCs and inhibit the expression of the co-stimulatory molecules such as CD40 and CD86. Furthermore, immethridine also inhibited the antigen-presenting function of DCs and T cell differentiation induced by DCs. Signaling pathway analysis demonstrated that the phosphorylation of NF-κB p65 but not ERK1/2 in DCs was inhibited after the treatment of immethridine. These data strongly suggested that immethridine could inhibit the function of DCs and indicated the therapeutic potential on EAE.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20500